Literature DB >> 12132523

Cushing's syndrome with a large pituitary adenoma producing both corticotropin-releasing hormone (CRH) and adrenocorticotropin (ACTH).

Yuya Yamada1, Akiko Ohashi, Toru Inoue, Katsuhiko Sakaguchi, Takahiro Tsujimura, Daisuke Okamoto, Hiroaki Itatani, Naomi Fujimoto, Kazumasa Kusaka, Hisako Fushimi.   

Abstract

A 57-year-old man showed high serum cortisol, plasma adrenocorticotropin (ACTH) and corticotropin-releasing hormone (CRH) levels with a large pituitary tumor and a prostatic cancer. High dose dexamethasone did not suppress cortisol secretion and CRH administration did not stimulate cortisol secretion. After surgical removal of the pituitary tumor, plasma CRH, ACTH and serum cortisol levels were normalized. Histological examinations showed pituitary adenoma and prostatic adenocarcinoma, and pituitary adenoma was stained with both anti-CRH and anti-ACTH antibodies, but prostatic cancer was not stained. A CRH-producing pituitary adenoma is a new type of Cushing's syndrome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12132523     DOI: 10.2169/internalmedicine.41.549

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

Review 1.  The corticotropin releasing factor system in cancer: expression and pathophysiological implications.

Authors:  Athina Kaprara; Kalliopi Pazaitou-Panayiotou; Alexandros Kortsaris; Ekaterini Chatzaki
Journal:  Cell Mol Life Sci       Date:  2010-02-09       Impact factor: 9.261

Review 2.  Ectopic cushing's syndrome due to corticotropin releasing hormone.

Authors:  Manouchehr Nakhjavani; Alireza Amirbaigloo; Soghra Rabizadeh; Fabio Rotondo; Kalman Kovacs; Ali A Ghazi
Journal:  Pituitary       Date:  2019-10       Impact factor: 4.107

Review 3.  Pituitary Gangliocytoma Producing TSH and TRH: A Review of "Gangliocytomas of the Sellar Region".

Authors:  Kiyohiko Sakata; Kana Fujimori; Satoru Komaki; Takuya Furuta; Yasuo Sugita; Kenji Ashida; Masatoshi Nomura; Motohiro Morioka
Journal:  J Clin Endocrinol Metab       Date:  2020-10-01       Impact factor: 5.958

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.